Latest Period
Q4 2025
Security Snapshot
Calidi Biotherapeutics, Inc. - Common Stock, $0.0001 par value (CLDI) Institutional Ownership
CUSIP: 320703408
13F Institutional Holders and Ownership History from Q3 2025 to Q1 2026
Institutions Reporting
27
Shares (Excl. Options)
448,323
Price
$1.17
- Type / Class
- Equity / Common Stock, $0.0001 par value
- Symbol
- CLDI on NYSE
- Shares outstanding
- 7,142,857
- Price per share
- $0.24
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 448,323
- Total reported value
- $524,682
- % of total 13F portfolios
- 0%
- Share change
- +237,292
- Value change
- +$271,225
- Number of holders
- 27
- Price from insider filings
- $0.24
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- CLDI - Calidi Biotherapeutics, Inc. - Common Stock, $0.0001 par value is tracked under CUSIP 320703408.
- 27 institutions reported positions in Q4 2025.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 27 to 1 between Q4 2025 and Q1 2026.
- Reported value moved from $524,682 to $2,426.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Official SEC Source
Backed by Form 13F
Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.
See Original FilingInvestment Quick Answers
What is CUSIP 320703408?
CUSIP 320703408 identifies CLDI - Calidi Biotherapeutics, Inc. - Common Stock, $0.0001 par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Continue Investment Research
- Latest 13F filings for new institutional portfolio disclosures.
- Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
- Latest 10-Q/10-K reports to cross-check issuer fundamentals.
- Recent insider transactions for management buying/selling context.
- SEC investors directory and top value investors for manager-level discovery.
- All institutional ownership pages to compare adjacent CUSIP pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 320703408:
Significant Owners of Calidi Biotherapeutics, Inc. - Common Stock, $0.0001 par value (CLDI) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 5% | 117,368 | Armistice Capital, LLC | 30 Jun 2025 | ||||
| Gavrilov Ognian Anguelov | 0.3% | -95% | $6,600 | -$224,400 | 20,000 | -97% | Gavrilov Ognian Anguelov | 31 Mar 2026 |
As of 31 Dec 2025, 27 institutional investors reported holding 448,323 shares of Calidi Biotherapeutics, Inc. - Common Stock, $0.0001 par value (CLDI). This represents 6.3% of the company’s total 7,142,857 outstanding shares.